午夜插插,噜噜噜影院,啪啪伊人网,欧美熟夫,景甜吻戏视频,男人强操性感蕾丝美女视频在线网站,日本美女跳舞视频

Welcome to chemicalbook!
+1 (818) 612-2111
RFQ
Try our best to find the right business for you.
Do not miss inquiry messages Please log in to view all inquiry messages.

Welcome back!

RFQ
skype
MY Account
Top
Postion:Product Catalog >Dolutegravir Impurity
Dolutegravir Impurity
  • Dolutegravir Impurity
  • Dolutegravir Impurity
  • Dolutegravir Impurity
  • Dolutegravir Impurity
  • Dolutegravir Impurity

Dolutegravir Impurity NEW

Price Get Latest Price
Package 10mg 50mg 100mg
Min. Order: 10mg
Supply Ability: 1000
Update Time: 2025-06-18

Product Details

Product Name: Dolutegravir Impurity CAS No.: 2374716-73-9
Min. Order: 10mg Purity: 99%+ HPLC
Supply Ability: 1000 Release date: 2025/06/18

Dolutegravir Impurity2374716-73-9

Article illustration

WhatsAPP: +86 17320513646
E-mail: anna@molcoo.com

    • Product Number: D021033
      English Name: Dolutegravir Impurity 33
      English Alias: N-(2,4-difluorobenzyl)-9-hydroxy-2-(4-hydroxybutan-2-yl)-1,8-dioxo-2,8-dihydro-1H-pyrido[1,2-a]pyrazine-7-carboxamide
      CAS Number: 2374716-73-9
      Molecular Formula: C??H??F?N?O?
      Molecular Weight: 419.38

    • Product Advantages

    • High purity and structural confirmation:HPLC purity ≥99.0%, confirmed by multiple methods including 1H NMR, 13C NMR, HRMS, and infrared spectroscopy, meeting the requirements of pharmacopoeias such as USP and EP for impurity reference standards.

    • Reliable stability:Stable for 36 months when stored at -20°C in the dark, with a degradation rate <1% after 14 days at room temperature in solution (e.g., methanol-water system), suitable for long-term quality monitoring and complex analytical scenarios.

    • Clear functional group characteristics:Contains hydroxyl, amide, and difluorobenzyl groups, enabling precise tracking of process risks from incomplete hydroxylation reactions or insufficient benzylation reagent selectivity in dolutegravir synthesis.


    • Applications

    • Pharmaceutical impurity detection:Used for LC-MS/MS detection of Impurity 33 in dolutegravir APIs and formulations, controlling its content ≤0.1% in accordance with ICH Q3A standards to ensure compliance with strict quality requirements for anti-HIV drugs.

    • Synthesis process optimization:In benzylation and hydroxylation reactions, monitoring impurity content (e.g., reducing impurity from 1.1% to 0.1% when adjusting reaction pH from acidic to neutral) optimizes reaction conditions to reduce by-product formation.

    • Analytical method development:Serves as a multi-functional group impurity reference standard for establishing specific detection methods, such as ultra-performance liquid chromatography-diode array detection (UPLC-DAD), achieving accurate quantification using characteristic UV absorption (limit of quantitation LOQ=0.05μg/mL).

    • Toxicological research support:Provides samples for evaluating the potential toxicity of fluorinated impurities, facilitating in vitro cytotoxicity tests and in vivo pharmacokinetic studies to meet FDA requirements for impurity safety assessment in anti-AIDS drugs.


    • Background Description
      Dolutegravir Impurity 33 is a multi-functional group impurity introduced during dolutegravir (an HIV integrase inhibitor) synthesis due to insufficient hydroxylation site selectivity or excessive benzylation reagents. The difluorobenzyl group in its structure may affect the drug's binding efficiency to integrase, while incomplete hydroxyl reactions may increase metabolic product toxicity. According to the ICH M7(R1) guideline, organofluorine compounds require genotoxicity assessment, making strict control of this impurity a key aspect of dolutegravir quality research. Current industry standards set the individual impurity limit at ≤0.1% with reference to ICH Q3B.

    • Research Status

    • Advances in detection technology:UPLC-MS/MS is employed using a C18 column (1.7μm, 2.1×100mm) with 0.1% formic acid aqueous solution-acetonitrile (gradient elution) as the mobile phase, achieving a detection limit (LOD) of 0.01ppm under multiple reaction monitoring (MRM) mode, suitable for quantitative analysis of trace fluorinated impurities.

    • Formation mechanism research:This impurity mainly originates from insufficient oxidant (e.g., hydrogen peroxide) dosage in hydroxylation reactions or non-selective substitution by benzylation reagents (e.g., 2,4-difluorobenzyl chloride). Increasing oxidant dosage (1.5equiv) and reacting at low temperature (0-5℃) can reduce impurity formation by over 80%.

    • Safety evaluation:In vitro HIV integrase inhibition tests show that the impurity has only 5% activity of the parent drug, but mild hepatic mitochondrial damage was observed in high-dose groups (200mg/kg) during a 28-day rat toxicity test, suggesting that reasonable limits (e.g., ≤0.08%) should be set based on toxicological data to ensure drug safety.

NOTE!

We can also customize related analogues and modified peptides including HPLC, MS, 1H-NMR, MS, HPLC, IR, UV, COA, MSDS.
This product is intended for laboratory use only!

WhatsAPP: +86 17320513646
E-mail: anna@molcoo.com


NEW IN STOCK!

The Molcoo Laboratory added drug impurity reference standards, including Baricitinib, Piperazine, Benzylpenicillin, Tranilast and multiple N-Nitroso drug impurities! Now available for immediate delivery! 











Company Profile Introduction

1. Drug standards and drug impurity reference substances: provide more than 20,000 kinds of spot impurity reference substances, with sufficient supply and same-day delivery. We have a professional R&D team and comprehensive quality control testing to ensure product quality and reliability. 2. Customized synthesis of impurities and new molecules: Quickly respond to the customized needs of CDE impurities, stably supply impurities that have established quality standards, and provide customized synthesis services for new compounds in the research and development of innovative drugs. 3. Preparation and separation of unknown impurities: With a professional impurity preparation and separation technical team and SFC preparation and separation instruments, we can solve the problems of impurity preparation in complex projects. 4. Process development of new drug intermediates: provide the supply of new drugs and new molecular impurities, process optimization services, as well as the screening and impurity analysis of commercialization routes. 5. Peptide synthesis: Provide customized peptide synthesis services, and cover all kinds of degradation impurities and process impurities generated in the research and development of peptide drugs. At the same time, it provides comprehensive structural confirmation data and customized testing services.

You may like

Recommended supplier

Product name Price   Suppliers Update time
$0.00/5mg
VIP1Y
Guangzhou Tosun Pharmaceutical Ltd
2025-01-26
$0.00/10mg
VIP2Y
ShenZhen H&D Pharmaceutical Technology Co., LTD
2024-04-22
$30.00/1mg
VIP5Y
TargetMol Chemicals Inc.
2025-07-07
INQUIRY